No Data
No Data
Century Therapeutics to Present Preclinical Data at ASGCT 28th Annual Meeting on Novel IPSC-Derived Cell Therapies for Autoimmune Diseases and Cancer
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $2
William Blair Maintains Century Therapeutics(IPSC.US) With Hold Rating
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $2
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Intuitive Surgical (ISRG) and Century Therapeutics (IPSC)
Piper Sandler Remains a Buy on Century Therapeutics (IPSC)